Abstract
Angiogenesis is a multistep program that involves the activation, proliferation, and migration of endothelial cells. In healthy body, except for reproductive cycle or embryogenesis, angiogenesis is strictly regulated by numerous factors to maintain homeostasis. Factors can be divided mainly in two categories, positive regulators and negative regulators. In pathological process like acute inflammation or wound repair, both positive and negative regulators are induced and activated, but quickly the response comes to the reduction. However, in oncogenesis, new vessel formation occurs repeatedly and chronically1-2. In the early stage of tumor progression, the alteration of the balance between positive regulators and negative regulators is limited only in the primary tumor site, but in the late stage/ clinical stage, this alteration is no longer localized in the local foci. Over expression of positive regulators and/or down regulation of negative regulators at systemic level are frequently observed. In this process, not only tumor cells but also various stromal cells such as macrophages, other leukocytes, fibroblasts and endothelial cells are responsible for the explosive induction of positive regulators. It is estimated that continuous interaction between tumor cells and stromal cells in a positive feedback loop enables a ceaseless. In this manuscript, we focused on the importance of stromal cells, particularly monocytic cells, and reviewed the role of cytokines in tumor angiogenesis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Folkman J., 1995, Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1 27–31.
Folkman J. et al., 1987, Angiogenic factors. Science 235: 442–447.
Gasparini G. et al., 1995, Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J. Clin. Oncol. 13: 765–782.
Toi M et al., 1996, Clinical significance of the determination of angiogenic factors. Eur J Cancer. 32A: 2513–2519.
Toi M. et al., 1995, Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin. Cancer Res. 1:961–964.
Toi M. et al., 1995, Expression of platelet-derived endothelial cell growth factor in human breast cancer. Int. J. Cancer 64: 79–82.
Gasparini G. et al., 1997, Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl. Cancer Inst. 89:139–147.
Linderholmm B. et al., 1998, Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol. 16: 3121–3128.
Eppenberger U. et al., 1998, Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J.Oncol. 16:3129–3136.
Ohta Y. et al., 1997, Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br. J. Cancer 76: 1041–1045.
Kitadai Y. et al., 1998, Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin. Cancer Res. 4: 2195–2200.
Takanami L. et al., 1997, Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 17:2811–2814.
Paley P.J. et al., 1997, Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98–106.
Maeda K. eg al., 1996, Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858–863.
Crew J.P. et al., 1997, Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 57:5281–52855
Sauter E.R. et al., 1999, Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. 5:775–782.
Abdulrauf S.I. et al., 1998, Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J. Neurosurg. 88:513–520.
Bellamy W.T. et al., 1999, Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59:728–733.
Salven P. et al., 1997, A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood 90: 3167–3172.
Carmehet P. et al., 1998, Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation an tumour angiogenesis. Nature. 394: 485–490.
Maxwell P.H. et al., 1997, Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci.U S A. 94: 8104–8109.
Maxwell P.H. et al., 1999, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271–275.
Brooks S.E. et al., 1998, Modulation of VEGF production by pH and glucose in retinal Muller cells. Curr. Eye Res. 17: 875–882.
Xiong M. et al., 1998, Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J. Pathol. 153: 587–598.
Satake S. et al., 1998, Up-regulation of vascular endothelial growth factor in response to glucosedeprivation. Cell 90: 161–168.
Solovey A. et al., 1999, Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood 93: 3824–3830.
Spyridopoulos I. et al., 1997, Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J. Mol. Cell. Cardiol. 29:1321–1330.
Nor J.E. et al., 1999, Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J Pathol. 154: 375–384.
Kondo S. et al., 1994, bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells. Exp. Cell Res. 213: 428–432.
Moghaddam K. et al., 1995, Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. 92: 998–1002.
Miyadera K. et al., 1995, Role of thymidine phosphorylase activity in tthe angiogenic effect of platelet-derived endothelial cell growth factor/ thymidine phosphorylase. Cancer Res. 55: 1687–1690.
Haraguchi M. et al. Angiogenic activity of enzymes. Nature 368, 198, 1994
Moghaddam A. et al., 1995, Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. 92: 998–1002.
O’Brien T. et al., 1995, Differential angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55: 510–513.
Reynolds K. et al., 1994, Association of ovarian malignancy with expression of plateletderived endothelial cell growth factor. J. Natl. Cancer Inst. 86: 1234–1238.
Eda H. et al., 1993, Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5’-deoxy-5-fluorouridine. Cancer Chem. Pharm., 32: 333–338..
Griffiths L. et al., 1997, The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/ thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res. 57: 570–572.
Nishino I et al., 1999, Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283:689–692.
Kitazono M. et al., 1998, Prevention of hypoxia-mduced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem. Biophys. Res. Commun. 253: 797–803.
Tanigawa N. et al., 1996, Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Lett. 108: 281–290.
Takebayashi Y. et al., 1996, Chinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 88: 1110–1117.
Imazano Y et al., 1997, Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J. Clin Oncol. 15: 2570–2578.
Koukourakis M.l. et al., 1998, Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br. J. Cancer 77. 1696–1703.
Takao S. et al., 1998, Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas. Clin. Cancer Res. 4: 1619–1624.
Toi M. et al., 1997, Co-ordination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications. Angiogenesis 1: 71–83
Hata K. et al., 1999, Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br. J. Cancer 79: 1848–1854.
Fox S.B. et al., 1997, Relationship of elevated tumour thymidine phosphorylase in nodepositive breast carcinomas to the effects of adjuvant CMF. Ann. Oncol. 8: 271–275.
Gasparini G. et al., 1999, Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J.Sci. Am. 5:101–111.
Colomer R. et al., 1997, Low levels of basic fibroblast growth (bFGF) are associated with a poor prognosis in human breast carcinoma. Br. J. Cancer 76: 1215–1220.
Thibault A. et al., 19898, A phase II study of 5-aza-2’deoxycytidine (decitabme) in hormone independent metastatic (D2) prostate cancer. Tumor. 84: 87–89.
Brattstrom D. et al., 1998, Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res. 18: 1123–1127.
Bredel M. et al., 1997, Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas. Clin. Cancer Res 3: 2157–2164.
Mantovani A. 1994, Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokmes. Lab. Invest. 71: 5–16.
Graves, D.T. et al., 1991, Biochem. Pharmacol. 41: 333–337, 1991.
Oppenheim, J. et al., 1991, Properties of the novel proinflammatory supergene intercrine cytokine family. Annu. Rev. Immunol., 9: 617–621.
Polverini P. et al., 1996, How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Er. J. Cancer. 32A: 2430–2437.
O’Sullivan C. et al., 1993, Secretion of epidermal growth factor by macrophages associated with breast carcinoma. The Lancet. 342: 148–149.
Falcone D. J. et al., 1993, Transforming growth factor-β1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J. Cell. Physiol. 155: 595–605.
Roger P. et al., 1994, Cathepsm D Immunostaining in Paraffin-Embedded Breast Cancer Cells and Macrophages. Human Pathol. 25: 863–871.
Heppner K. et al., 1996, Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149: 273–282.
Hildenbrand R. et al., 1995, Urokinase and macrophages in tumor angiogenesis. Br. J. Cancer 72: 818–823.
Toi M. et al., 1999, Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin. Can. Res. 5: 1131–1137.
Ishigaki S. et al., 1999, Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn. J. Cancer Res. 90: 516–522.
Toi M et al., 1991, Interleuk?n-4 is a potent mitogen for capillary endothelium. Biochem. Biophys. Res. Commun. 174: 1287–1293.
Fukushi J. et al., 1998, Novel biological function of Interleukin-4: Formation of tube-like structure by vascular endothelial cells in vitro and angiogenesis in vivo. Biochem. Biophy. Res. Commu. 250: 444–448.
Thornhill M.H. et al., 1990, IL-4 Regulates endothelial cell activation by IL-1, tumor nerosis factor, or IFN-γ1. J.Immunol. 145: 865–872.
Wojta J. et al., 1993, Interleukin-4 stimulates Expression of Urokinase-Type-Plasminogen activator in cultured human foreskin microvascular endothelial cells. Blood 81: 3285–3292
Masinovsky B. et al., 1990, IL-4 acts synergistically with IL-lβ to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J. Immunol. 145: 2886–2898.
Yao L. et al., 1996, Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. J. Exp. Med. 1, 184: 81–92.
Kuhn R.et al., 1991, Generation and analysis of interleukin-4 deficient mice. Science 254: 707–710.
Kopf M.et al., 1993, Disruption of the murine IL-4 gene blocks Th2 cytokine responsers. Nature. 362: 245–248.
Saleh M et al., 1999, Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J. Natl. Cancer Inst. 91: 438–445.
Volpert O.V. et al., 1998, Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 188: 1039–1046.
Koch A.E. et al., 1992, Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798–1801.
Hu D.E. et al., 1993, Interlerkin-8 stimulates angiogenesis in rats. Inflammation 17: 135–143.
Singh R.K. et al., 1994, Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54: 3242–3247.
Luca M. et al., 1997, Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151: 1105–1113.
Arenberg D.A. et al., 1996, Inhibition of interleukin-8 reduces tumorigencsis of human non-small cell lung cancer in SCID mice. J. Clin. Invst. 97: 2792–2802.
Galffy G. et al., 1999, Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 59: 367–371.
Kitadai Y. et al., 1998, expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am. J. Pathol. 152: 93–100.
Yoneda J. et al., 1998, Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. 90: 447–454.
Desbaillets I et al., 1997, Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J. Exp. Med. 186: 1201–1212.
Desbaillets I. et al., 1999, Regulation of interleuk?n-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene 18: 1447–1456.
Richards B.L. et al., 1997, Coexpression of ?nterleukin-8 receptors in head and neck squamous cell carcinoma. Am. J. Surg. 174: 507–512.
Eisma R.J. et al., 1999, Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope 109: 687–693.
Fiorentino D. F. et al., 1985, Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170: 2081–2095.
Fiorentino D. F. et al., 1991, IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146: 3444–3451.
Moore K.W. et al., 1993, Interleukin 10. Annu.Rev. Immunol. 11: 165–190.
Hsu D.H. et al., 1990, Expression of IL-10 activity by Epstein-Barr virus protein BCRF1. Science 250: 830–832.
Hsu D.H. et al., 1992, Differencial effects of interleukin-4 and-10 on interleukin-2-induced interferon-γ synthesis and lymphokine-activated killer activity, int. Immunol. 4: 563–569.
Huang S. et al., 1996, Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin. Cancer Res. 2: 1969–1979.
Richter G. et al., 1993, Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 53: 4134–4137.
Kundu N. et al., 1997, Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol. 180: 55–61.
Stearns M.E. et al., 1999, Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloprotemase (MMP)-2/MMP-9 secretion. Clin. Cancer Res. 5: 189–196.
Stearns M.E. et al., 1999, Role of interleukin 10 and transforming growth factor βl in the angiogenesis and metastasis of human prostate primary tumor lines from orthoropic implantsi in severe combined immunodeficiency mice. Clin. Cancer Res. 5: 711–720. 3.
Watanabe M. et al., 1997, Regulation of local host-mediated anti-tumor mechanisms by cytokines (Direct and indirect effects on leukocyte recruiment and an angiogenesis. Am. J. Pathol. 150: 1869–1881.
Dias S. et al., 1998, IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int. J. Cancer 78: 361–365.
Strieter R.M. et al., 1995, Interferon γ-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophy. Res. Commu. 210: 51–57.
Arenberg D.A. et al., 1996, Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184: 981–992.
Oppenheim J. J. et al., 1991, Properties of the novel proinflammatory supergene “intercrine” cytokine family. Annu. Rev. Immunol. 9: 617–648
Sarris, A.H. et al., 1993, Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J. Exp. Med. 178: 1127–1132.
Sarris, A.H. et al., 1995, Cytokine loops involving interferon-γ and IP-10, a cytokine chenotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneus T-cell lymphoma? Blood 86: 651–658.
Valente A.J. et al., 1988, Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry 27: 4162–4168
Yosimura T. et al., 1990, Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes. J. Immunol. 145: 292–297
Gerszten R.E. et al., 1999, MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 22: 398: 718–723.
Bian Z.M. et al., 1999, IL-4 potentiates IL-1 beta-and TNF-alpha-srimulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells. Curr. Eye. Res. 18: 349–357.
Koyama S. et al., 1999, Monocyte chemotactic factors released from type II pneumocyte-like cells in response to TNF-alpha and IL-1 alpha. Eur. Respir. J. 13: 820–828.
Biswas P. et al.,1999, Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 91: 258–265.
Marumo T. et al., 1999, Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 48: 1131–1137.
Negus R.P. et al., 1995, The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 95: 2391–2396.
Altenburg A. et al., 1999, CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J. Immunol. 162: 4140–4147.
Amann B. et al., 1998, Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br. J. Urol. 82: 118–121.
Gabrilovich D.I. et al., 1996, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2: 1096–1103.
Melder R.J. et al., 1996, During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 2: 992–997
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bando, H., Toi, M. (2000). Tumor Angiogenesis, Macrophages, and Cytokines. In: Maragoudakis, M.E. (eds) Angiogenesis. Advances in Experimental Medicine and Biology, vol 476. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4221-6_21
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4221-6_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6895-3
Online ISBN: 978-1-4615-4221-6
eBook Packages: Springer Book Archive